Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars
- PMID: 26849514
- PMCID: PMC5218811
- DOI: 10.1038/nbt.3474
Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars
Figures

References
-
- Health Canada. GUIDANCE FOR SPONSORS: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) Health Canada -Publications. 2010;17 2010/03/05.
-
- EMEA Comparability of biotechnological/biological products subject to changes in their manufacturing process. CPMP/ICH/5721/03. 2006;13
-
- US FDA. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Office of Communications US FDA. 2012:1–20. UCM291134.
-
- US FDA. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Produc. Office of Communications US FDA. 2012:1–25. UCM291128.
-
- Gabrielson JP, Weiss WF. 4th Technical decision-making with higher order structure data: starting a new dialogue. J Pharm Sci. 2015;104:1240–1245. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources